Melchiore Giganti

Melchiore Giganti

Auto-generated profile, based on publicly available information

Melchiore Giganti

Radiology Section, Department of Translational Medicine, University of Ferrara, 44121 Ferrara, Italy

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 August 2022 in Molecules
Verified
Journal Article
Open access
PDF file
Licia UccelliLicia Uccelli
Licia Uccelli
Petra MartiniPetra Martini
Petra Martini
Luca UrsoLuca Urso
Luca Urso
TGTeresa Ghirardi
Teresa Ghirardi
LMLorenza Marvelli
Lorenza Marvelli
Alessandra BoschiAlessandra Boschi
Alessandra Boschi
In recent decades, the use of alpha; pure beta; or beta/gamma emitters in oncology, endocrinology, and interventional cardiology rheumatology, has proved to be an important alternative to the most common therapeutic regimens. Among radionuclides used for therapy in nuclear medicine, two rhenium radioisotopes are of particular relevance: rhenium-186 and rhenium-188. The first is routinely produced in nuclear reactors by direct neutron activation of rhenium-186 via 185Re(n,γ)186Re nuclear reaction. Rhenium-188 is produced by the decay of the parent tungsten-188. Separation of rhenium-188 is mainly performed using a chromatographic 188W/188Re generator in which tungsten-188 is adsorbed on the alumina column, similar to the 99Mo/99mTc generator system, and the radionuclide eluted in saline solution. The application of rhenium-186 and rhenium-188 depends on their specific activity. Rhenium-186 is produced in low specific activity and is mainly used for labeling particles or diphosphonates for bone pain palliation. Whereas, rhenium-188 of high specific activity can be used for labeling peptides or bioactive molecules. One of the advantages of rhenium is its chemical similarity with technetium. So, diagnostic technetium analogs labeled with radiorhenium can be developed for therapeutic applications. Clinical trials promoting the use of 186/188Re-radiopharmaceuticals is, in particular, are discussed.

13 September 2021 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
Licia UccelliLicia Uccelli
Licia Uccelli
Alessandra BoschiAlessandra Boschi
Alessandra Boschi
CCCorrado Cittanti
Corrado Cittanti
Petra MartiniPetra Martini
Petra Martini
Stefano PanareoStefano Panareo
Stefano Panareo
MBMirco Bartolomei
Mirco Bartolomei
The PRRT (Peptide Receptor Radionuclide Therapy) is a promising modality treatment for patients with inoperable or metastatic neuroendocrine tumors (NETs). Progression-free survival (PFS) and overall survival (OS) of these patients are favorably comparable with standard therapies. The protagonist in this type of therapy is a somatostatin-modified peptide fragment ([Tyr3] octreotide), equipped with a specific chelating system (DOTA) capable of creating a stable bond with β-emitting radionuclides, such as yttrium-90 and lutetium-177. In this review, covering twenty five years of literature, we describe the characteristics and performances of the two most used therapeutic radiopharmaceuticals for the NETs radio-treatment: [90Y]Y-DOTATOC and [177Lu]Lu-DOTATOC taking this opportunity to retrace the most significant results that have determined their success, promoting them from preclinical studies to application in humans.

10 February 2022 in Molecules
Verified
Journal Article
Open access
PDF file
Alessandra BoschiAlessandra Boschi
Alessandra Boschi
Licia UccelliLicia Uccelli
Licia Uccelli
LMLorenza Marvelli
Lorenza Marvelli
CCCorrado Cittanti
Corrado Cittanti
MGMelchiore Giganti
Melchiore Giganti
Petra MartiniPetra Martini
Petra Martini
The favorable nuclear properties in combination with the rich coordination chemistry make technetium-99m the radioisotope of choice for the development of myocardial perfusion tracers. In the early 1980s, [99mTc]Tc-Sestamibi, [99mTc]Tc-Tetrofosmin, and [99mTc]Tc-Teboroxime were approved as commercial radiopharmaceuticals for myocardial perfusion imaging in nuclear cardiology. Despite its peculiar properties, the clinical use of [99mTc]Tc-Teboroxime was quickly abandoned due to its rapid myocardial washout. Despite their widespread clinical applications, both [99mTc]Tc-Sestamibi and [99mTc]Tc-Tetrofosmin do not meet the requirements of an ideal perfusion imaging agent due to their relatively low first-pass extraction fraction and high liver absorption. An ideal radiotracer for myocardial perfusion imaging should have a high myocardial uptake; a high and stable target-to-background ratio with low uptake in the lungs, liver, stomach during the image acquisition period; a high first-pass myocardial extraction fraction and very rapid blood clearance; and a linear relationship between radiotracer myocardial uptake and coronary blood flow. Although it is difficult to reconcile all these properties in a single tracer, scientific research in the field has always channeled its efforts in the development of molecules that are able to meet the characteristics of ideality as much as possible. This short review summarizes the developments in 99mTc myocardial perfusion tracers, which are able to fulfill hitherto unmet medical needs and serve a large population of patients with heart disease, and underlines their strengths and weaknesses, the lost and found opportunities thanks to the developments of the new ultrafast SPECT technologies.

28 January 2025 in La radiologia medica
Verified
Journal Article
Open access
PDF file
Luca UrsoLuca Urso
Luca Urso
LMLuigi Manco
Luigi Manco
CCCorrado Cittanti
Corrado Cittanti
SASara Adamantiadis
Sara Adamantiadis
KSKlarisa Elena Szilagyi
Klarisa Elena Szilagyi
MGMelchiore Giganti
Melchiore Giganti
Purpose: Build machine learning (ML) models able to predict pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) in breast cancer (BC) patients based on conventional and radiomic signatures extracted from baseline [18F]FDG PET/CT. Material and methods: Primary tumor and the most significant lymph node metastasis were manually segmented in baseline [18F]FDG PET/CT of 52 newly diagnosed BC patients. Clinical parameters, NAC and conventional semiquantitative PET parameters were collected. The standard of reference considered was surgical pCR after NAC (ypT0;ypN0). Eight-hundred-fifty-four radiomic features (RFts) were extracted from both PET and CT datasets, according to IBSI; robust RFTs were selected. The cohort was split in training (70%) and validation (30%) sets. Four ML Models (Clinical Model, CT Model, PET Model_T and PET Model_T + N) each one with 3 learners (Random Forest (RF), Neural Network and Stochastic Gradient Descendent) were trained and tested using RFts and clinical signatures. PET Models were built considering robust RFTs extracted from either primary tumor alone (PET Model_T) or also including the reference lymph node (PET Model_T + N). Results: 72 pathological uptakes (52 primary BC and 20 lymph node metastasis) at [18F]FDG PET/CT were segmented. pCR occurred in 44.2% cases. Twelve, 46 and 141 robust RFts were selected from CT Model, PET Model_T and PET Model_T + N, respectively. PET Models showed better performance than CT and Clinical Models. The best performances were obtained by the RF algorithm of the PET Model_T + N (AUC = 0.83;CA = 0.74;TP = 78%;TN = 72%). Conclusion: ML models trained on PET/CT radiomic features extracted from primary BC and lymph node metastasis could concur in the prediction of pCR after NAC and improve BC management.

12 February 2019 in Molecules
Verified
Journal Article
Open access
PDF file
Licia UccelliLicia Uccelli
Licia Uccelli
Petra MartiniPetra Martini
Petra Martini
CCCorrado Cittanti
Corrado Cittanti
ACAldo Carnevale
Aldo Carnevale
LMLoretta Missiroli
Loretta Missiroli
Alessandra BoschiAlessandra Boschi
Alessandra Boschi
Academic journals have published a large number of papers in the therapeutic nuclear medicine (NM) research field in the last 10 years. Despite this, a literature analysis has never before been made to point out the research interest in therapeutic radionuclides (RNs). For this reason, the present study aims specifically to analyze the research output on therapeutic radiometals from 2008 to 2018, with intent to quantify and identify global trends in scientific literature and emphasize the interdisciplinary nature of this research field. The data search targeted conventional (131I, 90Y, 177Lu, 188Re, 186Re, 153Sm, 89Sr, 186Er) and emergent (67Cu, 47Sc, 223Ra, 166Ho, 161Tb, 149Tb, 212Pb/212Bi, 225Ac, 213Bi, 211At, 117mSn) RNs. Starting from this time frame, authors have analyzed and interpreted this scientific trend quantitatively first, and qualitatively after.

19 June 2019 in CardioVascular and Interventional Radiology
Verified
Journal Article
Closed access
PDF file
CFChiara Floridi
Chiara Floridi
ACAldo Carnevale
Aldo Carnevale
EFE. M. Fumarola
E. M. Fumarola
SSS. Schampaert
S. Schampaert
FFFederico Fontana
Federico Fontana
GCGianpaolo Carrafiello
Gianpaolo Carrafiello